Risk assessment in pulmonary arterial hypertension (PAH): Insights from the GRIPHON study
暂无分享,去创建一个
H. Ghofrani | R. Benza | G. Simonneau | O. Sitbon | M. Hoeper | V. McLaughlin | V. Tapson | K. Chin | L. Rubin | S. Gaine | I. Lang | H. Ghofrani | N. Galiè | R. Channick | R. Preiss | I. Lang | M. Hoeper | L. Rubin | R. Channick | L. Di Scala | G. Simonneau | V. McLaughlin
[1] R. Benza,et al. Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. , 2019, Chest.
[2] M. Humbert,et al. Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension , 2019, European Respiratory Journal.
[3] Z. Jing,et al. Risk stratification and medical therapy of pulmonary arterial hypertension , 2019, European Respiratory Journal.
[4] R. Weintraub,et al. Retrospective validation of the REVEAL 2.0 Risk Score with the Australian and New Zealand Pulmonary Hypertension Registry Cohort. , 2019, Chest.
[5] S. Söderberg,et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension , 2018, European heart journal.
[6] J. Barberà,et al. Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score. , 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[7] M. Humbert,et al. Risk assessment in pulmonary arterial hypertension , 2018, European Respiratory Journal.
[8] M. Humbert,et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension , 2017, European Respiratory Journal.
[9] S. Rosenkranz,et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model , 2017, European Respiratory Journal.
[10] R. Benza,et al. Assessing risk in pulmonary arterial hypertension: what we know, what we don't , 2017, European Respiratory Journal.
[11] Simon Gibbs,et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension , 2015, European Respiratory Journal.
[12] M. Humbert,et al. Validation of two predictive models for survival in pulmonary arterial hypertension , 2015, European Respiratory Journal.
[13] H. Ghofrani,et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. , 2014, The New England journal of medicine.
[14] R. Benza,et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. , 2012, Chest.
[15] Christopher S Coffey,et al. Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.
[16] S. Lagakos. The challenge of subgroup analyses--reporting without distorting. , 2006, The New England journal of medicine.